Condition (MeSH)
Factor XIII Deficiency
ClinicalTrials.gov lists 8 trials for Factor XIII Deficiency or a narrower condition beneath it. CSL Behring has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with Factor XIII Deficiency itself; the rest are tagged with a narrower condition beneath it.
When did Factor XIII Deficiency trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2017 | 1 |
| 2015 | 1 |
| 2009 | 3 |
| 2008 | 1 |
| 2007 | 1 |
| 2000 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 8 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Factor XIII Deficiency trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
| Not applicable | 1 |
| Observational | 4 |
How many Factor XIII Deficiency trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 6 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Factor XIII Deficiency trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| CSL Behring | 3 |
Which serious adverse events do Factor XIII Deficiency trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Appendicitis | 1 | 1 |
| Brain mass | 1 | 1 |
| Catheter related infection | 1 | 1 |
| Chest pain with radiation to left arm | 1 | 1 |
| Factor XIII inhibition | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Factor XIII Deficiency? (22)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Acquired factor XIII deficiency is associated with mortality and is not linked to hypocalcemia. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis | 2026 | Yes |
| Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration. | Blood | 2024 | Yes |
| Acquired FXIII Deficiency is Associated with High Morbidity. | Thrombosis and haemostasis | 2022 | Yes |
| COVID-19 is Associated with an Acquired Factor XIII Deficiency. | Thrombosis and haemostasis | 2021 | Yes |
| Novel Factor XIII variant identified through whole-genome sequencing in a child with intracranial hemorrhage. | Cold Spring Harbor molecular case studies | 2018 | Yes |
Showing 5 of 22 publications.
Prevalence (4)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Congenital factor XIII deficiency | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Congenital factor XIII deficiency | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Congenital factor XIII deficiency | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Congenital factor XIII deficiency | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Congenital factor XIII deficiency | 331 | Exact | Orphadata Science knowledge files, Product 1 |
| Congenital factor XIII deficiency | 331 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.